Come and discover innovative approaches to handle the reimbursement restrictions dictated by European pricing authorities.

Pricing and reimbursement experts examine the tactical importance of price optimization throughout the product lifecycle. The key issues affecting pricing and reimbursement disciplines are identified and the market environments of individual countries are assessed.

This forum offers lifecycle pricing strategies of new and established drugs, including actionable recommendations and detailed case studies along with forecasts for future pricing scenarios in major markets.

Join us in this interactive, experience driven learning environment and get the answers you need to shape your strategy.

 

Amgen, Switzerland, International Pricing Manager

Akrikhin, Russia, Business Development Director

Baxter, Belgium, Director, Government Affairs and Public Policy, Europe

CAHTAR, Spain, Director AATRM  

Dutch Healthcare Insurance Board (CVZ), Netherlands, Secretary of the Dutch Pharmaceutical Aid Committee

(G-BA), Germany, Chairman of the Federal Joint Committee

GlaxoSmithKline, France, Director, Government Affairs

Menarini Group, Italy, Group Director, Regulatory and Pricing

Merz, Germany, Director Pharmacoeconomics, Pricing & Reimbursement

NICE, UK, Associate Director Single Technology Appraisals

WHO Regional Office for Europe, Denmark, Regional Adviser Health Technology and Pharmaceuticals      

Wyeth, Switzerland, Senior Director, Pricing & Reimbursement E/ME/AC, Europe

 

 

• Benchmarking  different pricing & reimbursement systems across the European markets
• Achieving competitive advantage in current pricing & reimbursement environment
• Keeping the optimal price throughout a drug’s life
• Successfully navigating the HTA maze
• The role of health economics for pricing
• Best practices in improving market access speed

 

Vice Presidents, Heads, Directors, Senior Managers and Managers of:

Pricing, Market Pricing, Commercial Pricing, Pricing Strategies, Pricing & Reimbursement, Health Economics, Outcomes Research, Market Access,  Pharmacoeconomics, Regulatory Affairs, Governmental Affairs, Public Affairs, Public Policy, Operations, Government bodies and Regulatory bodies